+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07140783

Study of 0.75% Phentolamine Ophthalmic Solution Versus Placebo for Adults with Night Vision Loss After Keratorefractive Surgery

Led by Opus Genetics, Inc · Updated on 2026-10-14

580

Participants Needed

20

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the safety and effectiveness of Phentolamine Ophthalmic Solution POS in adults who have previously undergone keratorefractive surgery and now experience decreased vision under low light, or mesopic, conditions. This Phase 3 trial compares POS to a placebo to determine if POS can improve night vision in this group. Participants will be randomly assigned to receive either 0.75% Phentolamine Ophthalmic Solution or a placebo eye drop once daily for two weeks. Weekly clinic visits during this period will include checkups and tests. Participants will also maintain a diary to record their daily medication use each evening. Throughout the study, participants will undergo various vision tests and questionnaires to measure changes in visual acuity under mesopic conditions and effects on night driving difficulties. Safety and vision improvements will be closely monitored during the two-week treatment and at follow-up visits. The trial is expected to last until August 2027.

CONDITIONS

Brief Title

OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

Research Team

S

Study Director

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here